Industry: Life Science
Research from Medical University of South Carolina
Funding Received: SBIR/STTR Matching Grant, PDF Grant, SC Launch, Inc. Investment
FirstString Research is a clinical-stage biopharmaceutical company. Their breakthrough solutions provide therapies for inflammation and injury based medical conditions. The therapies mitigate excessive inflammation by calming the inflamed tissue and rebooting the body’s normal injury response. FirstString is focused on diseases associated with dysregulation of inflammatory processes and modulation of injury response, such as cutaneous radiation injury, radiation dermatitis, and wounds.
The company was formed based on technology from the Medical University of South Carolina (MUSC) in 2007 by Dr. Ghatnekar. While Dr. Ghatnekar was a post-doctoral fellow at MUSC he studied regenerative medicine and discovered the translational benefits of the aCT peptide, which led to the formation of FirstString Research. FirstString’s technology is based on connexin-based peptides (α-Connexin Carboxyl-Terminal or aCT peptides) and the company has an exclusive license from MUSC for the connexin technology platform.